ModernVivo Joins Debiopharm Portfolio for AI-driven Advancements in Preclinical Studies

Debiopharm Innovation Fund has invested in ModernVivo, an AI-driven platform that seeks to revolutionize the design and execution of in vivo studies. By moving away from traditional trial-and-error approaches, ModernVivo's platform enables research and development teams to conduct preclinical studies that are smarter, faster, and more ethical. Their advanced AI models help optimize animal studies to achieve more relevant and successful real-world outcomes, effectively bridging the gap between laboratory research and clinical applications. This partnership underscores ModernVivo's potential to address significant inefficiencies in current preclinical protocols. For Debiopharm, this investment enhances its portfolio with innovative technology that supports pharmaceutical companies in their quest for groundbreaking research. With Debiopharm's backing, ModernVivo plans to extend its global reach and continue the advancement of its platform.